Indoleamine 2,3-dioxygnase 1 (IDO1) expression in gliomas has been suggested to be another important Treg recruiter, potentially via chemokine induction, and IDO upregulation is associated with a decrease in survival in glioma patients [136]. Here, IDO1 is linked to central nervous system cancer.